1. Home
  2. NWBI vs MESO Comparison

NWBI vs MESO Comparison

Compare NWBI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northwest Bancshares Inc.

NWBI

Northwest Bancshares Inc.

HOLD

Current Price

$12.48

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$19.19

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWBI
MESO
Founded
1896
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NWBI
MESO
Price
$12.48
$19.19
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$15.00
$24.00
AVG Volume (30 Days)
868.2K
191.8K
Earning Date
01-23-2026
08-28-2025
Dividend Yield
6.54%
N/A
EPS Growth
13.78
N/A
EPS
0.86
N/A
Revenue
$564,562,000.00
$17,198,000.00
Revenue This Year
$7.91
$465.44
Revenue Next Year
$9.01
$75.37
P/E Ratio
$14.16
N/A
Revenue Growth
15.71
191.39
52 Week Low
$10.75
$9.61
52 Week High
$14.64
$22.00

Technical Indicators

Market Signals
Indicator
NWBI
MESO
Relative Strength Index (RSI) 60.81 70.18
Support Level $12.14 $16.43
Resistance Level $12.54 $17.65
Average True Range (ATR) 0.24 0.66
MACD 0.08 0.36
Stochastic Oscillator 96.43 95.46

Price Performance

Historical Comparison
NWBI
MESO

About NWBI Northwest Bancshares Inc.

Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: